Moderna, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Moderna, Inc. (MRNA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $1.44 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-07-31
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $710.00M, a 52.38% decline year-over-year.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $732.00M, a 62.13% decline year-over-year.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $929.00M, a 1.64% increase year-over-year.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $1.21B, a 8.81% increase year-over-year.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $5.56B, a 0.02% increase from fiscal 2024.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $5.56B, a 0.23% decline from fiscal 2023.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $5.58B, a 76.93% increase from fiscal 2022.
- Moderna, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $3.15B, a 135.50% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $710.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $1.44B 10-Q · filed 2026-07-31 | $2.37B derived: sum of 3 quarters · filed 2026-07-31 | $3.58B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $732.00M 10-Q · filed 2026-05-01 | $1.66B derived: sum of 2 quarters · filed 2026-05-01 | $2.87B derived: sum of 3 quarters · filed 2026-05-01 | $4.36B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $929.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.14B derived: sum of 2 quarters · filed 2026-02-20 | $3.63B derived: sum of 3 quarters · filed 2026-07-31 | $5.56B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $1.21B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.70B derived: sum of 2 quarters · filed 2026-07-31 | $4.63B 10-Q · filed 2025-11-06 | $5.55B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $1.49B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $3.42B 10-Q · filed 2026-07-31 | $4.34B derived: sum of 3 quarters · filed 2026-07-31 | $5.45B derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $1.93B 10-Q · filed 2026-05-01 | $2.85B derived: sum of 2 quarters · filed 2026-05-01 | $3.96B derived: sum of 3 quarters · filed 2026-05-01 | $5.92B derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $914.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.03B derived: sum of 2 quarters · filed 2026-02-20 | $3.99B derived: sum of 3 quarters · filed 2026-02-20 | $5.56B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $1.11B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.08B derived: sum of 2 quarters · filed 2025-11-06 | $4.65B 10-Q · filed 2025-11-06 | $5.51B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $1.96B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $3.54B 10-Q · filed 2025-08-01 | $4.40B derived: sum of 3 quarters · filed 2026-02-20 | $5.85B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $1.57B 10-Q · filed 2025-05-01 | $2.44B derived: sum of 2 quarters · filed 2026-02-20 | $3.88B derived: sum of 3 quarters · filed 2026-02-20 | $5.79B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $864.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.31B derived: sum of 2 quarters · filed 2026-02-20 | $4.21B derived: sum of 3 quarters · filed 2026-02-20 | $5.58B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $1.45B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.35B derived: sum of 2 quarters · filed 2024-11-07 | $4.71B 10-Q · filed 2024-11-07 | $5.64B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $1.90B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.26B 10-Q · filed 2024-08-01 | $4.19B derived: sum of 3 quarters · filed 2025-02-21 | $5.01B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $1.36B 10-Q · filed 2024-05-02 | $2.29B derived: sum of 2 quarters · filed 2025-02-21 | $3.10B derived: sum of 3 quarters · filed 2025-02-21 | $4.07B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $929.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $1.74B derived: sum of 2 quarters · filed 2025-02-21 | $2.71B derived: sum of 3 quarters · filed 2025-02-21 | $3.15B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $813.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.78B derived: sum of 2 quarters · filed 2023-11-03 | $2.22B 10-Q · filed 2023-11-03 | $2.48B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | $968.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.41B 10-Q · filed 2023-08-03 | $1.67B derived: sum of 3 quarters · filed 2024-02-23 | $1.89B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | $441.00M 10-Q · filed 2023-05-04 | $704.00M derived: sum of 2 quarters · filed 2024-02-23 | $919.00M derived: sum of 3 quarters · filed 2024-02-23 | $1.44B derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $263.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $478.00M derived: sum of 2 quarters · filed 2024-02-23 | $999.00M derived: sum of 3 quarters · filed 2024-02-23 | $1.34B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $215.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $736.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.07B 10-Q · filed 2022-11-03 | $1.46B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $521.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $860.00M 10-Q · filed 2022-08-03 | $1.25B derived: sum of 3 quarters · filed 2023-02-24 | $1.48B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $339.00M 10-Q · filed 2022-05-04 | $728.00M derived: sum of 2 quarters · filed 2023-02-24 | $959.00M derived: sum of 3 quarters · filed 2023-02-24 | $1.21B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $389.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $620.00M derived: sum of 2 quarters · filed 2023-02-24 | $868.00M derived: sum of 3 quarters · filed 2023-02-24 | $1.14B 10-K · filed 2023-02-24 | $1.14B 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $231.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $479.00M derived: sum of 2 quarters · filed 2021-11-04 | $748.00M 10-Q · filed 2021-11-04 | $748.15M 10-Q · filed 2020-10-30 | $993.15M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $248.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $517.00M 10-Q · filed 2021-08-05 | $516.91M 10-Q · filed 2020-08-06 | $762.15M derived: sum of 3 quarters · filed 2022-02-25 | $946.37M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $269.00M 10-Q · filed 2021-05-06 | $269.73M 10-Q · filed 2020-05-07 | $514.15M derived: sum of 2 quarters · filed 2022-02-25 | $698.37M derived: sum of 3 quarters · filed 2022-02-25 | $858.06M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $245.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $429.37M derived: sum of 2 quarters · filed 2022-02-25 | $589.06M derived: sum of 3 quarters · filed 2022-02-25 | $993.00M 10-K · filed 2022-02-25 | $993.18M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $184.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $343.91M derived: sum of 2 quarters · filed 2020-10-30 | $747.85M 10-Q · filed 2020-10-30 | $1.04B derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $159.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $563.63M 10-Q · filed 2020-08-06 | $853.48M derived: sum of 3 quarters · filed 2021-02-26 | $1.05B derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $403.94M 10-Q · filed 2020-05-07 | $693.79M derived: sum of 2 quarters · filed 2021-02-26 | $888.94M derived: sum of 3 quarters · filed 2021-02-26 | $997.50M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $289.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $485.00M derived: sum of 2 quarters · filed 2021-02-26 | $593.56M derived: sum of 3 quarters · filed 2021-02-26 | $783.37M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $195.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $303.71M derived: sum of 2 quarters · filed 2019-11-06 | $493.52M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $108.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $298.38M 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $189.81M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $800.44M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $675.20M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |